Information Needed to Conduct First-in-Human Oncology Trials in the United States: A View from a Former FDA Medical Reviewer : CCRSENDEROWICZ, Adrian M.Clinical cancer research (Print). 2010, Vol 16, Num 6, pp 1719-1725, issn 1078-0432, 7 p.Article

Similarities and Differences in the Oncology Drug Approval Process between FDA and European Union with Emphasis on In Vitro Companion Diagnostics : PRECISION MEDICINESENDEROWICZ, Adrian M; PFAFF, Otmar.Clinical cancer research (Print). 2014, Vol 20, Num 6, pp 1445-1452, issn 1078-0432, 8 p.Article

Cyclin-dependent kinases as new targets for the prevention and treatment of cancerSENDEROWICZ, Adrian M.Hematology/oncology clinics of North America. 2002, Vol 16, Num 5, issn 0889-8588, viii, 1229-1253 [25 p.]Article

Small molecule modulators of cyclin-dependent kinases for cancer therapySENDEROWICZ, Adrian M.Oncogene (Basingstoke). 2000, Vol 19, Num 56, pp 6600-6606, issn 0950-9232Article

Role of cell cycle control and cyclin-dependent kinases in breast cancerSENDEROWICZ, Adrian M.Breast disease. 2002, Vol 15, pp 33-52, issn 0888-6008, 20 p.Article

RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cellsMUKHOPADHYAY, Utpal K; SENDEROWICZ, Adrian M; FERBEYRE, Gerardo et al.Cancer research (Baltimore). 2005, Vol 65, Num 7, pp 2872-2881, issn 0008-5472, 10 p.Article

Small-molecule cyclin-dependent kinase modulatorsSENDEROWICZ, Adrian M.Oncogene (Basingstoke). 2003, Vol 22, Num 42, pp 6609-6620, issn 0950-9232, 12 p.Article

UCN-01-induced cell cycle arrest requires the transcriptional induction of p21^waf1/cip1 by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathwayFACCHINETTI, Maria M; DE SIERVI, Adriana; TOSKOS, Doreen et al.Cancer research (Baltimore). 2004, Vol 64, Num 10, pp 3629-3637, issn 0008-5472, 9 p.Article

Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasmsSENDEROWICZ, Adrian M.Cancer chemotherapy and pharmacology. 2003, Vol 52, pp S61-S73, issn 0344-5704, SUP1Conference Paper

Phenoxodiol, a novel isoflavone, induces G₁ arrest by specific loss in cyclin-dependent kinase 2 activity by p53-lndependent induction of p21^WAF1/CIP1AGUERO, Martin F; FACCHINETTI, Maria M; SHELEG, Zhanna et al.Cancer research (Baltimore). 2005, Vol 65, Num 8, pp 3364-3373, issn 0008-5472, 10 p.Article

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical developmentSUOPING ZHAI; SENDEROWICZ, Adrian M; SAUSVILLE, Edward A et al.The Annals of pharmacotherapy. 2002, Vol 36, Num 5, pp 905-911, issn 1060-0280Article

CDK2 Activation in Mouse Epidermis Induces Keratinocyte Proliferation but Does Not Affect Skin Tumor DevelopmentMACIAS, Everardo; MILIANI DE MARVAL, Paula L; DE SIERVI, Adriana et al.The American journal of pathology. 2008, Vol 173, Num 2, pp 526-535, issn 0002-9440, 10 p.Article

Perifosine, a novel alkylphospholipid, induces p21^WAF1 expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrestPATEL, Vyomesh; LAHUSEN, Tyler; SY, Terence et al.Cancer research (Baltimore). 2002, Vol 62, Num 5, pp 1401-1409, issn 0008-5472Article

Effects of α₁-Acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporineSPARREBOOM, Alex; HUACHEN CHEN; FIGG, William D et al.Clinical cancer research. 2004, Vol 10, Num 20, pp 6840-6846, issn 1078-0432, 7 p.Article

Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6MESSMANN, Richard A; ULLMANN, Claudio Dansky; SENDEROWICZ, Adrian M et al.Clinical cancer research. 2003, Vol 9, Num 2, pp 562-570, issn 1078-0432, 9 p.Article

Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27^KIP1PATEL, Vyomesh; LAHUSEN, Tyler; LEETHANAKUL, Chidchanok et al.Clinical cancer research. 2002, Vol 8, Num 11, pp 3549-3560, issn 1078-0432, 12 p.Article

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasmsSAUSVILLE, Edward A; ARBUCK, Susan G; JING, Xiu-Xian et al.Journal of clinical oncology. 2001, Vol 19, Num 8, pp 2319-2333, issn 0732-183XArticle

Clinical pharmacology of flavopiridol following a 72-hour continuous infusionRUDEK, Michelle A; BAUER, Kenneth S; FIGG, William D et al.The Annals of pharmacotherapy. 2003, Vol 37, Num 10, pp 1369-1374, issn 1060-0280, 6 p.Article

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasmsTAN, Antoinette R; HEADLEE, Donna; SENDEROWICZ, Adrian M et al.Journal of clinical oncology. 2002, Vol 20, Num 19, pp 4074-4082, issn 0732-183X, 9 p.Article

A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasmsFIGG, William D; MONGA, Manish; RYAN, Qin C et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 5, pp 955-967, issn 0344-5704, 13 p.Article

Characterization of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseasesBACHRICH, Thomas; THALHAMMER, Therese; JÄGER, Walter et al.Hepatology (Baltimore, Md.). 2001, Vol 33, Num 5, pp 1053-1059, issn 0270-9139Article

In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes : Involvement of udp-glucuronosyltransferases 1A1 and 1A9HAGENAUER, Birgit; SALAMON, Alexandra; THALHAMMER, Therese et al.Drug metabolism and disposition. 2001, Vol 29, Num 4, pp 407-414, issn 0090-9556, 1Article

Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cellsROBEY, Robert W; MEDINA-PEREZ, Wilma Y; NISHIYAMA, Kenryu et al.Clinical cancer research. 2001, Vol 7, Num 1, pp 145-152, issn 1078-0432Article